(TLSA) Tiziana Life Sciences - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: BMG889121031

TLSA: Monoclonal Antibody, Small Molecule Inhibitor

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a biotechnology company specializing in the discovery and development of innovative therapeutics for oncology and immunology. The companys pipeline includes a diverse range of candidates targeting various inflammatory and autoimmune diseases. Its lead product candidate, Foralumab (TZLS-401), is a first-in-class, fully human anti-CD3 monoclonal antibody designed to modulate T-cell responses. This candidate is being investigated for multiple indications, including Crohns disease, ulcerative colitis, graft-versus-host disease, multiple sclerosis, type-1 diabetes, psoriasis, and rheumatoid arthritis. Foralumabs unique mechanism of action, which involves partial agonism of the CD3 receptor, aims to restore immune homeostasis while minimizing the risk of severe immune activation associated with full agonist anti-CD3 antibodies.

The company also develops Milciclib (TZLS-201), a small molecule inhibitor with broad-spectrum activity against cyclin-dependent kinases (CDKs) and Src family kinases. This candidate has shown promise in treating solid tumors, including hepatocellular carcinoma (HCC), and is being explored in combination with other therapies to enhance efficacy. Additionally, Tiziana is advancing TZLS-501, a fully human monoclonal antibody targeting the interleukin-6 (IL-6) receptor, which plays a key role in chronic inflammation and oncology. IL-6 signaling is implicated in various diseases, including rheumatoid arthritis, inflammatory bowel disease, and certain cancers, making TZLS-501 a versatile candidate with potential across multiple indications.

Founded in 1998 and headquartered in London, United Kingdom, Tiziana Life Sciences has established itself as a pioneer in the development of novel immunomodulatory therapies. The companys focus on addressing unmet medical needs in autoimmune diseases and oncology positions it as a key player in the biotechnology sector. Tizianas strategic approach includes leveraging its expertise in monoclonal antibodies and small molecule inhibitors to deliver targeted therapies with improved safety and efficacy profiles.

Objective: Tiziana Life Sciences Ltd aims to revolutionize the treatment of autoimmune and inflammatory diseases by developing cutting-edge therapeutics that target the underlying mechanisms of immune dysregulation. The company is committed to advancing its pipeline through rigorous clinical testing and strategic collaborations to bring innovative treatments to patients in need. 3-Month Forecast: Based on the provided and , TLSA is currently trading at $1.15, above its 20-day SMA ($0.87) and 50-day SMA ($0.80) but below its 200-day SMA ($0.92). The stocks average true range (ATR) of $0.10 indicates low volatility. The companys market cap of $133.93M reflects its current valuation, though the P/B ratio of 72.20 suggests significant investor confidence relative to book value. Over the next three months, TLSA is likely to face resistance near $1.50 (historical resistance level) and support at $1.00 (psychological level). The stocks price action will depend on its ability to maintain momentum above its 20-day and 50-day SMAs. If TLSA breaks above $1.50, it could signal a bullish reversal, targeting $2.00. Conversely, a failure to hold above $1.00 may lead to a retest of the lower end of its 52-week range. The low ATR suggests small price movements, but the stocks fundamentals and clinical progress will remain key drivers of investor sentiment.

Additional Sources for TLSA Stock

TLSA Stock Overview

Market Cap in USD 175m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2000-03-24

TLSA Stock Ratings

Growth 5y 6.84%
Fundamental -38.7%
Dividend 0.0%
Rel. Strength Industry 235
Analysts -
Fair Price Momentum 1.59 USD
Fair Price DCF -

TLSA Dividends

No Dividends Paid

TLSA Growth Ratios

Growth Correlation 3m 42.6%
Growth Correlation 12m 35.5%
Growth Correlation 5y -64.9%
CAGR 5y 11.95%
CAGR/Max DD 5y 0.13
Sharpe Ratio 12m -0.04
Alpha 215.76
Beta -1.64
Volatility 137.72%
Current Volume 377.2k
Average Volume 20d 886.5k
What is the price of TLSA stocks?
As of March 16, 2025, the stock is trading at USD 1.57 with a total of 377,219 shares traded.
Over the past week, the price has changed by -7.10%, over one month by +98.23%, over three months by +68.93% and over the past year by +209.30%.
Is Tiziana Life Sciences a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Tiziana Life Sciences (NASDAQ:TLSA) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.66 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TLSA as of March 2025 is 1.59. This means that TLSA is currently overvalued and has a potential downside of 1.27%.
Is TLSA a buy, sell or hold?
Tiziana Life Sciences has no consensus analysts rating.
What are the forecast for TLSA stock price target?
According to ValueRays Forecast Model, TLSA Tiziana Life Sciences will be worth about 1.7 in March 2026. The stock is currently trading at 1.57. This means that the stock has a potential upside of +8.92%.
Issuer Forecast Upside
Wallstreet Target Price 3 91.1%
Analysts Target Price 3 91.1%
ValueRay Target Price 1.7 8.9%